An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia

References

• Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiol Rev. 2021 Jan 1;101(1):259–301. doi: 10.1152/physrev.00045.2019
   PubMed Web of Science ®Google Scholar
• McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006 Feb;10(2):127–135. doi: 10.1016/j.ejpain.2005.01.014
   PubMed Web of Science ®Google Scholar
• Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003 Jun;26(6):1790–1795. doi: 10.2337/diacare.26.6.1790
   PubMed Web of Science ®Google Scholar
• van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014 Apr;155(4):654–662.
   PubMed Web of Science ®Google Scholar
• Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006 Oct 5;52(1):77–92. doi: 10.1016/j.neuron.2006.09.021
   PubMed Web of Science ®Google Scholar
• Bodman MA, Varacallo M. Peripheral diabetic neuropathy. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2024. [cited 2024 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK442009/
   Google Scholar
• Shankar Kikkeri N, Nagalli S. Trigeminal Neuralgia. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2024. [cited 2024 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554486/
   Google Scholar
• Gabutti G, Valente N, Kuhdari P, et al. Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine. J Med Microbiol. 2016 Dec;65(12):1363–1369.
   PubMedGoogle Scholar
• Zorzoli E, Pica F, Masetti G, et al. Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies. Aging Clin Exp Res. 2018 Jul;30(7):693–702.
   PubMed Web of Science ®Google Scholar
• Chen I, Lui F. Neuroanatomy, neuron action potential In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing;2024. [cited 2024 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK546639/
   Google Scholar
• West SJ, Bannister K, Dickenson AH. et al. Circuitry and plasticity of the dorsal horn–toward a better understanding of neuropathic pain. Neuroscience. 2015 Aug 6;300:254–275. doi: 10.1016/j.neuroscience.2015.05.020
   PubMed Web of Science ®Google Scholar
• Tibbs GR, Posson DJ, Goldstein PA. Voltage-gated ion channels in the PNS: novel therapies for neuropathic pain? Trends Pharmacol Sci. 2016 Jul;37(7):522–542. doi: 10.1016/j.tips.2016.05.002
   PubMed Web of Science ®Google Scholar
• Baskozos G, Dawes JM, Austin JS, et al. Comprehensive analysis of long noncoding RNA expression in dorsal root ganglion reveals cell-type specificity and dysregulation after nerve injury. Pain. 2019 Feb;160(2):463–485.
   PubMed Web of Science ®Google Scholar
• Czeschik JC, Hagenacker T, Schäfers M, et al. TNF-alpha differentially modulates ion channels of nociceptive neurons. Neurosci Lett. 2008 Apr 4;434(3):293–298. doi: 10.1016/j.neulet.2008.01.070
   PubMed Web of Science ®Google Scholar
• Kress GJ, Mennerick S. Action potential initiation and propagation: upstream influences on neurotransmission. Neuroscience. 2009 Jan 12;158(1):211–222. doi: 10.1016/j.neuroscience.2008.03.021
   PubMed Web of Science ®Google Scholar
• Jewett BE, Sharma S. Physiology, GABA. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2024. [cited 2024 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK513311/
   Google Scholar
• Stahl SM, Porreca F, Taylor CP, et al. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci. 2013 Jun;34(6):332–339.
   PubMed Web of Science ®Google Scholar
• Hange N, Poudel S, Ozair S, et al. Managing chronic neuropathic pain: recent advances and new challenges. Neurol Res Int. 2022 Oct 12;2022:1–14.
   Web of Science ®Google Scholar
• Fitridge R, Thompson M editors. Mechanisms of vascular disease: a reference book for vascular specialists [Internet]. Adelaide (AU): University of Adelaide Press; 2011. [cited 2024 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK534260/
   Google Scholar
• Dhaliwal JS, Spurling BC, Molla M. Duloxetine. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2024. [cited 2024 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK549806/
   Google Scholar
• Rogers AH, Farris SG. A meta-analysis of the associations of elements of the fear-avoidance model of chronic pain with negative affect, depression, anxiety, pain-related disability and pain intensity. Eur J Pain. 2022 Sep;26(8):1611–1635. doi: 10.1002/ejp.1994
   PubMed Web of Science ®Google Scholar
• Nijs J, Mairesse O, Neu D, et al. Sleep disturbances in chronic pain: neurobiology, assessment, and treatment in Physical Therapist practice. Phys Ther. 2018 May 1;98(5):325–335. doi: 10.1093/ptj/pzy020
   PubMed Web of Science ®Google Scholar
• Dale R, Stacey B. Multimodal treatment of chronic pain. Med Clin North Am. 2016 Jan;100(1):55–64. doi: 10.1016/j.mcna.2015.08.012
   PubMed Web of Science ®Google Scholar
• Skelly AC, Chou R, Dettori JR, et al. Noninvasive nonpharmacological treatment for chronic pain: a systematic review update [internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 [cited 2024 Jan 24]. (AHRQ Comparative Effectiveness Reviews). Available from: http://www.ncbi.nlm.nih.gov/books/NBK556229/
   Google Scholar
• DeFrates S, Cook AM, Smith KM, et al. Pharmacologic treatment of neuropathic pain following spinal cord injury. Orthopedics. 2011 Mar;34(3):203–207. doi: 10.3928/01477447-20110124-19
   PubMed Web of Science ®Google Scholar
• Pang ZP, Südhof TC. Cell biology of Ca2±triggered exocytosis. Curr Opin Cell Biol. 2010 Aug;22(4):496–505. doi: 10.1016/j.ceb.2010.05.001
   PubMed Web of Science ®Google Scholar
• Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009 Sep;10(9):895–926. doi: 10.1016/j.jpain.2009.06.012
   PubMed Web of Science ®Google Scholar
• Ghayur MN, Yaman H. Potential adverse consequences of combination therapy with gabapentin and Pregabalin. Case Rep Med. 2021;2021:1–4. doi: 10.1155/2021/5559981
   Web of Science ®Google Scholar
• Cavalli E, Mammana S, Nicoletti F, et al. The neuropathic pain: an overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019;33:2058738419838383. doi: 10.1177/2058738419838383
   Web of Science ®Google Scholar
• Sheffler ZM, Patel P, Abdijadid S. Antidepressants. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2024. [cited 2024 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK538182/
   Google Scholar
• Gebhart GF. Descending modulation of pain. Neurosci Biobehav Rev. 2004 Jan;27(8):729–737. doi: 10.1016/j.neubiorev.2003.11.008
   PubMed Web of Science ®Google Scholar
• Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med. 2019 Jun;20(Suppl 1):S2–12.
   PubMedGoogle Scholar
• Wang SM, Han C, Bahk WM, et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018 May;54(2):101–112.
   PubMedGoogle Scholar
• Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains. Curr Opin Neurol. 2009 Oct;22(5):467–474. doi: 10.1097/WCO.0b013e3283311e13
   PubMed Web of Science ®Google Scholar
• Güloglu C, Orak M, Ustündag M, et al. Analysis of amitriptyline overdose in emergency medicine. Emerg med J. 2011 Apr;28(4):296–299.
   PubMed Web of Science ®Google Scholar
• Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ. 1998 Nov 17;159(10):1245–1252.
   PubMed Web of Science ®Google Scholar
• David DJ, Gourion D. Antidepressant and tolerance: determinants and management of major side effects. Encephale. 2016 Dec;42(6):553–561. doi: 10.1016/j.encep.2016.05.006
   PubMed Web of Science ®Google Scholar
• Dhesi M, Maldonado KA, Maani CV. Tramadol. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2024. [cited 2024 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK537060/
   Google Scholar
• Tramadol (oral route) proper use - mayo clinic [internet]. [cited 2024 Jan 25]. Available from: https://www.mayoclinic.org/drugs-supplements/tramadol-oral-route/proper-use/drg-20068050
   Google Scholar
• Duehmke RM, Derry S, Wiffen PJ, et al. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017 Jun 15;2017(6):CD003726. doi: 10.1002/14651858.CD003726.pub4
   Google Scholar
• Peppin JF, Pappagallo M. Capsaicinoids in the treatment of neuropathic pain: a review. Ther Adv Neurol Disord. 2014 Jan;7(1):22–32. doi: 10.1177/1756285613501576
   PubMed Web of Science ®Google Scholar
• Yang X, Wei X, Mu Y, et al. A review of the mechanism of the central analgesic effect of lidocaine. Medicine (Baltimore). 2020 Apr 24;99(17):e19898. doi: 10.1097/MD.0000000000019898
   PubMed Web of Science ®Google Scholar
• Chang A, Rosani A, Quick J. Capsaicin. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2024. [cited 2024 Jan 25]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK459168/
   Google Scholar
• Derry S, Wiffen PJ, Moore RA, et al. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014 Jul 24;2014(7):CD010958.
   PubMedGoogle Scholar
• Ordóñez Gallego A, González Barón M, Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298–307. doi: 10.1007/s12094-007-0057-9
   PubMed Web of Science ®Google Scholar
• Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain. 2008 Aug;12(6):804–813. doi: 10.1016/j.ejpain.2007.12.010
   PubMed Web of Science ®Google Scholar
• Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013 Apr;260(4):984–997.
   PubMed Web of Science ®Google Scholar
• Holbech JV, Bach FW, Finnerup NB, et al. Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial. Pain. 2015 May;156(5):958–966.
   PubMed Web of Science ®Google Scholar
• Irving GA, Backonja M, Rauck R, et al. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain. 2012 Feb;28(2):101–107.
   PubMed Web of Science ®Google Scholar
• Holbech JV, Jung A, Jonsson T, et al. Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process. J Pain Res. 2017;10:1467–1475. doi: 10.2147/JPR.S138099
   PubMed Web of Science ®Google Scholar
• Xia CC, Yu LH, Yue N. Du Y Ri, Che L muge, Yu J she. Research progress on the mechanism of chronic neuropathic pain. IBRO Neurosci Rep. 2022 Dec 20;14:80–85. doi: 10.1016/j.ibneur.2022.12.007
   PubMedGoogle Scholar
• Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015 Jun;17(2):111–126. doi: 10.31887/DCNS.2015.17.2/dionescu
   PubMed Web of Science ®Google Scholar
• Discovery of (S)-1-((2′,6-Bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): a highly selective, CNS penetrable, and orally active adaptor protein-2 associated kinase 1 inhibitor in clinical trials for the treatment of neuropathic pain. J Med Chem [Internet]. [cited 2024 Jan 25]. Available from. https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c02131
   Google Scholar
• Conner SD, Schmid SL. Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis. J Cell Bio. 2002 Mar 4;156(5):921–929. doi: 10.1083/jcb.200108123
   PubMed Web of Science ®Google Scholar
• Abdel-Magid AF. Inhibitors of adaptor-associated kinase 1 (AAK1) may treat neuropathic pain, schizophrenia, Parkinson’s disease, and other disorders. ACS Med Chem Lett. 2017 May 26;8(6):595–597. doi: 10.1021/acsmedchemlett.7b00208
   PubMedGoogle Scholar
• Mettlen M, Chen PH, Srinivasan S, et al. Regulation of Clathrin-Mediated Endocytosis. Annu Rev Biochem. 2018 Jun 20;87(1):871–896. doi: 10.1146/annurev-biochem-062917-012644
   PubMedGoogle Scholar
• Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Adv Pharmacol. 2006;54:1–27.
   PubMedGoogle Scholar
• Bundrant L, Hunt TL, Banks P, et al. Results of two phase 1, randomized, double-blind, placebo-controlled, studies (ascending single-dose and multiple-dose studies) to determine the safety, tolerability, and pharmacokinetics of orally administered LX9211 in healthy participants. Clin Ther. 2021 Jun;43(6):1029–1050.
   PubMed Web of Science ®Google Scholar
• BUSUI R, PATEL A, SANG CN, et al. 103-OR: LX9211, an orally-administered, non-opioid, AAK1 inhibitor for painful diabetic peripheral neuropathy—results from a randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Diabetes. 2023 Jun 20;72(Supplement_1):103–OR. doi: 10.2337/db23-103-OR
   Google Scholar
• Hinckley CA, Kuryshev Y, Sers A, et al. Characterization of vixotrigine, a broad-spectrum voltage-gated sodium channel blocker. Mol Pharmacol. 2021 Jan;99(1):49–59.
   PubMed Web of Science ®Google Scholar
• Motoike HK, Liu H, Glaaser IW, et al. The Na+ channel inactivation gate is a molecular complex: a novel role of the COOH-terminal domain. J Gen Physiol. 2004 Feb;123(2):155–165.
   PubMed Web of Science ®Google Scholar
• Witty DR, Alvaro G, Derjean D, et al. Discovery of Vixotrigine: a novel use-dependent sodium channel blocker for the treatment of trigeminal neuralgia. ACS Med Chem Lett. 2020 Jul 16;11(9):1678–1687. doi: 10.1021/acsmedchemlett.0c00263
   PubMed Web of Science ®Google Scholar
• Herrero JF, Laird JM, López-García JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol. 2000 Jun;61(2):169–203. doi: 10.1016/S0301-0082(99)00051-9
   PubMed Web of Science ®Google Scholar
• Faber CG, Attal N, Lauria G, et al. Efficacy and safety of vixotrigine in idiopathic or diabetes-associated painful small fibre neuropathy (CONVEY): a phase 2 placebo-controlled enriched-enrolment randomised withdrawal study. EClinicalMedicine. 2023 May;59:101971.
   PubMedGoogle Scholar
• Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol [Internet]. [cited 2024 Jan 25]. Available from: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30005-4/fulltext
   Web of Science ®Google Scholar
• Zajączkowska R, Mika J, Leppert W, et al. Mirogabalin-A novel selective ligand for the α2δ calcium channel subunit. Pharmaceuticals (Basel). 2021 Jan 31;14(2):112. doi: 10.3390/ph14020112
   PubMedGoogle Scholar
• Kim JY, Abdi S, Huh B, et al. Mirogabalin: could it be the next generation gabapentin or pregabalin? Korean J Pain. 2021 Jan 1;34(1):4–18. doi: 10.3344/kjp.2021.34.1.4
   PubMed Web of Science ®Google Scholar
• Dolphin AC. Voltage-gated calcium channel α 2δ subunits: an assessment of proposed novel roles. F1000Res. 2018 Nov 21;7:F1000 Faculty Rev-1830. doi: 10.12688/f1000research.16104.1
   PubMedGoogle Scholar
• Calcium Control of Neurotransmitter Release - PMC [Internet]. [cited 2024 Jan 25]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249630/
   Google Scholar
• Cunningham MO, Woodhall GL, Thompson SE, et al. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci. 2004 Sep;20(6):1566–1576.
   PubMed Web of Science ®Google Scholar
• Tzellos TG, Papazisis G, Toulis KA, et al. A2delta ligands gabapentin and pregabalin: future implications in daily clinical practice. Hippokratia. 2010 Apr;14(2):71–75.
   PubMed Web of Science ®Google Scholar
• Domon Y, Arakawa N, Inoue T, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018 Jun;365(3):573–582.
   PubMed Web of Science ®Google Scholar
• Kato J, Matsui N, Kakehi Y, et al. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019 May;160(5):1175–1185.
   PubMed Web of Science ®Google Scholar
• Vinik A, Rosenstock J, Sharma U, et al. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253–3261.
   PubMed Web of Science ®Google Scholar
• Kessler JA, Shaibani A, Sang CN, et al. Gene therapy for diabetic peripheral neuropathy: a randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin Transl Sci. 2021 May;14(3):1176–1184.
   PubMed Web of Science ®Google Scholar
• Tetsunaga T, Tetsunaga T, Nishida K, et al. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study. J Orthop Surg Res. 2020 May 26;15(1):191. doi: 10.1186/s13018-020-01709-3
   PubMed Web of Science ®Google Scholar
• Pharmacotherapy for neuropathic pain: a review - PubMed [Internet]. [cited 2024 Jan 25]. Available from: https://pubmed.ncbi.nlm.nih.gov/29178034/
   Google Scholar
• van Velzen M, Dahan A, Niesters M. Neuropathic pain: challenges and opportunities. Front Pain Res (Lausanne). 2020 Aug 7;1:1. doi: 10.3389/fpain.2020.00001
   PubMedGoogle Scholar
• Ebens A, Brose K, Leonardo ED, et al. Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron. 1996 Dec;17(6):1157–1172.
   PubMed Web of Science ®Google Scholar